KURA

AI MemoPost-earnings T+3

Kura Oncology

As of 2026-08-04/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FIT-001 darlifarnib/cabozantinib follow-up supports pipeline optionality • 2026-07-27

Base target: $10 / p=50% prob

Biggest risk

The investment case remains dependent on clinical execution, enrollment, durability of commercial uptake, and future readouts. Missing Q2 earnings evidence, absent analyst revisions, limited recent news coverage, and a low-coverage peer set make it difficult to validate the post-earnings thesis. Insider sales are a risk signal but do not establish operating weakness. [#SEC-FORM4-2026-06-22]

Invalidation

Break below $6 or thesis failure.

What would change my mind?

KOMZIFTI has early commercial traction and broad payer access, while ziftomenib's AML combination programs and darlifarnib's FIT-001 development provide multiple potential clinical value inflections. The primary-source operating evidence is constructive, but the Q2 follow-up remains unconfirmed.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-04

Base target

$10

p=50%

Bull target

$18

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings evidence gap remains unresolved
Durable KOMZIFTI commercial uptake could support rerating
AML combination and frontline readouts remain the primary value inflection

BearKey bullets

Biopharma valuation is highly event-driven; disappointing data or delayed milestones could cause a sharp price decline.
Early KOMZIFTI revenue and prescription activity may not yet demonstrate durable commercial scale or repeat utilization.
KOMET-017, KOMET-007, KOMET-008, and FIT-001 remain exposed to enrollment, safety, efficacy, regulatory, and timeline risk.

WatchKey bullets

FIT-001 darlifarnib/cabozantinib follow-up supports pipeline optionality

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $10 (p=50%)

Target spread vs base: +80% / -40%

Scenario probabilities

Bull Target: $18 (p=20%)Base Target: $10 (p=50%)Bear Target: $6 (p=30%)

Commentary

Primary-source evidence remains constructive on early commercialization and pipeline activity, but the scheduled T+3 earnings follow-up could not be completed on earnings-specific evidence: no confirmed Q2 company release, transcript, analyst revision, or attributed post-print market reaction was found. Social context is absent, recent packet news is empty, and the low-coverage peer set is loose. This is a cautious monitoring setup rather than a validated bullish reset.

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings evidence gap remains unresolved
Durable KOMZIFTI commercial uptake could support rerating
AML combination and frontline readouts remain the primary value inflection

Scenarios

Bull Target (Scenario probability)

$18 / p=20% prob

Base Target (Scenario probability)

$10 / p=50% prob

Bear Target (Scenario probability)

$6 / p=30% prob

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-27
FIT-001 darlifarnib/cabozantinib follow-up supports pipeline optionality
Kura announced updated Phase 1a FIT-001 data at the July 27 KCRS investor event and said randomized Phase 1b enrollment is ongoing, with a registrational study planned for 2028. The source supports an event-driven pipeline hook, but the packet lacks detailed primary readout results. [#IR-2026-07-14] ([IR release](https://kuraoncology.gcs-web.com/news-releases/news-release-details/kura-oncology-present-first-long-term-follow-data-further))
Prob 55.00% • Move 8.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Post-earnings evidence gap remains unresolved
2026-08-04
The scheduled T+3 follow-up does not include a confirmed Q2 2026 company release, SEC earnings exhibit, transcript, consensus comparison, analyst revision, or market-reaction attribution. This limits near-term signal quality and favors monitoring over directional conviction. ([Kura investor page](https://kuraoncology.gcs-web.com/))
Prob 90% • Move -3% • Priced-in 55%

Long-term Catalysts

Months to a year

Durable KOMZIFTI commercial uptake could support rerating
2026-12-31
Kura reported $5.8 million of net product revenue, 85 new patient starts, 157 total prescriptions, and more than 93% payer coverage in its first full commercial quarter. The forward test is whether repeat prescribing, switching, combination use, and payer access remain durable; Q2 confirmation is unavailable in the checked evidence. [#SEC-8K-2026-05-12] ([SEC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/kura-ex99_1.htm))
Prob 60% • Move 12% • Priced-in 45%
AML combination and frontline readouts remain the primary value inflection
2027-08-04
The company cited ongoing KOMET-017 Phase 3 enrollment, KOMET-007 and KOMET-008 combination programs, and multiple 2026 data readouts intended to establish ziftomenib as a broadly combinable AML backbone. Cash and anticipated collaboration payments were described as sufficient to support the program through initial KOMET-017 topline results, subject to execution and funding timing. [#SEC-8K-2026-05-12] ([SEC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/kura-ex99_1.htm))
Prob 58% • Move 15% • Priced-in 50%

Risks

Biopharma valuation is highly event-driven; disappointing data or delayed milestones could cause a sharp price decline.
Early KOMZIFTI revenue and prescription activity may not yet demonstrate durable commercial scale or repeat utilization.
KOMET-017, KOMET-007, KOMET-008, and FIT-001 remain exposed to enrollment, safety, efficacy, regulatory, and timeline risk.
No confirmed Q2 2026 earnings release, SEC earnings exhibit, transcript, consensus surprise, or analyst revision was available in the checked evidence as of 2026-08-04.
Recent Form 4 activity included open-market sales by the Chief Medical Officer and Chief Commercial Officer; this is insider-activity context only and not evidence of operating results. [#SEC-FORM4-2026-06-22] [#SEC-FORM4-2026-05-22]

Peers

Symbol	Summary
GERN	Same-sector, similarly sized biopharma peer in the packet; useful only as a loose small-cap development/commercialization comparison, not a direct AML read-through.
DSGN	Same-sector, similarly sized biotechnology peer; provides broad event-driven biotech context but no direct indication or asset overlap is established in the packet.
DBVT	Same-sector, similarly sized biotechnology peer; a loose valuation and execution comparator with limited direct relevance to Kura's AML and darlifarnib programs.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

Loading AI feed…

Symbol

Summary

GERN

Same-sector, similarly sized biopharma peer in the packet; useful only as a loose small-cap development/commercialization comparison, not a direct AML read-through.

DSGN

Same-sector, similarly sized biotechnology peer; provides broad event-driven biotech context but no direct indication or asset overlap is established in the packet.

DBVT

Same-sector, similarly sized biotechnology peer; a loose valuation and execution comparator with limited direct relevance to Kura's AML and darlifarnib programs.